Multicentre retrospective analysis of second allogeneic HSCT outcomes for haematologic malignancies in Korea

被引：0
|
作者：
Kim, K. H. [1 ]
Jung, C. W. [2 ]
Jang, J. H. [2 ]
Kim, K. [2 ]
Ahn, H. K. [2 ]
Won, J. H. [1 ]
Hong, D. S. [3 ]
Moon, J. H. [4 ]
Sohn, S. K. [4 ]
Kim, Y. K. [5 ]
Yang, D. H. [5 ]
Lee, J. J. [5 ]
Kim, H. J. [5 ]
Kim, J. S. [6 ]
Min, Y. H. [6 ]
Kim, D. Y. [7 ]
Lee, J. H. [7 ]
Lee, J. H. [7 ]
Lee, K. H. [7 ]
Kim, I. [8 ]
Yoon, S. S. [8 ]
Park, S. [8 ]
Lee, S. M. [9 ]
Joo, Y. D. [9 ]
Jun, H. J. [10 ]
Kim, D. H. [2 ]
机构：
[1] Soonchunhyang Univ Hosp, Seoul, South Korea
[2] Samsung Med Ctr, Seoul, South Korea
[3] Soonchunhyang Univ Hosp, Puchon, South Korea
[4] Kyungpook Natl Univ Hosp, Taegu, South Korea
[5] Chonnam Natl Univ, Sch Med, Kwangju, South Korea
[6] Yonsei Univ, Severance Hosp, Seoul 120749, South Korea
[7] Asan Med Ctr, Seoul, South Korea
[8] Seoul Natl Univ, Coll Med, Seoul, South Korea
[9] Busan Paik Hosp, Pusan, South Korea
[10] Konyang Univ Hosp, Taejon, South Korea
来源：
BONE MARROW TRANSPLANTATION | 2010年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 50 条
  • [41] Allogeneic HSCT in therapy-associated AML and MDS after treatment for lymphoma: A retrospective single-center analysis
    Wenge, Daniela Vanessa
    Reicherts, Christian
    Mikesch, Jan-Henrik
    Groth, Christoph
    Wethmar, Klaus
    Schliemann, Christoph
    Mesters, Rolf
    Kessler, Torsten
    Khandanpour, Cyrus
    Schmitz, Norbert
    Lenz, Georg
    Stelljes, Matthias
    BONE MARROW TRANSPLANTATION, 2019, 54 : 165 - 166
  • [42] Excellent Outcomes of the Second Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies with Reduced Toxicity Conditioning and Donor Change
    Zhao, Yongqiang
    Song, Yanzhi
    Li, Zhihui
    Yang, Fan
    Li, Feifei
    Yang, Dongfang
    Wu, Tong
    BLOOD, 2021, 138
  • [43] Clinical characteristics and outcomes of critically ill patients with COVID-19 in ICU: A multicentre retrospective cohort study in Korea
    Kim, Seong Min
    Chae, Ganghee
    Kim, Junghyun
    Joh, Joon-Sung
    Park, Tae Yun
    Baek, Ae-Rin
    Kim, Won-Young
    Jegal, Yang Jin
    Chung, Chi Ryang
    Lee, Jinwoo
    Park, Joo Hun
    Song, Jin Woo
    RESPIROLOGY, 2023, 28 : 319 - 320
  • [44] SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR SOLID ORGAN MALIGNANCIES AFTER ALLOGENEIC HSCT: A RETROSPECTIVE, MULTICENTRIC STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY
    Brijs, Jan
    Peczynski, Christophe
    Boreland, William
    Cuoghi, Angela
    Maertens, Johan
    Mohty, Mohamad
    Kroeger, Nicolaus
    Nakov, Philipp
    Broers, Annoek E. C.
    Eder, Matthias
    Arroyo, Concepcion Herrera
    Kaufmann, Martin
    Ram, Ron
    Schaap, Michel
    Penack, Olaf
    Konecke, Christian
    Moiseev, Ivan
    Schoemans, Helene
    Peric, Zinaida
    BONE MARROW TRANSPLANTATION, 2024, 59 : 582 - 584
  • [45] Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie
    Aerts, I
    Pacquement, H
    Doz, F
    Mosseri, V
    Desjardins, L
    Sastre, X
    Michon, J
    Rodriguez, J
    Schlienger, P
    Zucker, JM
    Quintana, E
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (10) : 1522 - 1529
  • [46] EBMT Survey on adolescents with ALL in second complete remission of given allogeneic HSCT. Analysis on behalf of the PDs and AL WPs
    Dini, G.
    Labopin, M.
    Cornish, J.
    Lawson, S.
    Bertrand, Y.
    Potter, M.
    Sedlacek, P.
    Ljungman, P.
    Locatelli, F.
    Hough, R.
    Balduzzi, A.
    Aljurf, M.
    Handgretinger, R.
    Gibson, B.
    Elarouci, N.
    Fossati, M.
    Lanino, E.
    Rocha, V.
    Peters, C.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S261 - S262
  • [47] Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
    Ruutu, T.
    de Wreede, L. C.
    van Biezen, A.
    Brand, R.
    Mohty, M.
    Dreger, P.
    Duarte, R.
    Peters, C.
    Garderet, L.
    Schonland, S.
    Gratwohl, A.
    Niederwieser, D.
    de Witte, T.
    Kroger, N.
    BONE MARROW TRANSPLANTATION, 2015, 50 (12) : 1542 - 1550
  • [48] Prognostic factors for outcome of patients undergoing allogeneic HSCT from unrelated and related donors for AML and MDS: A retrospective analysis.
    Graef, T
    Vaupel, M
    Fenk, R
    Ruf, L
    Zohren, F
    Haas, R
    Gattermann, N
    Germing, U
    Kobbe, G
    BLOOD, 2005, 106 (11) : 334A - 334A
  • [49] Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood
    Day, James W.
    Elfeky, Reem
    Nicholson, Bethany
    Goodman, Rupert
    Pearce, Rachel
    Fox, Thomas A.
    Worth, Austen
    Booth, Claire
    Veys, Paul
    Carpenter, Ben
    Hough, Rachael
    Gaspar, H. Bobby
    Titman, Penny
    Ridout, Deborah
    Workman, Sarita
    Hernandes, Fernando
    Sandford, Kit
    Laurence, Arian
    Campbell, Mari
    Burns, Siobhan O.
    Morris, Emma C.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (06) : 1230 - 1243
  • [50] The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes
    Nishikawa, Takuro
    Inagaki, Jiro
    Nagatoshi, Yoshihisa
    Fukano, Reiji
    Nakashima, Kentaro
    Ito, Nobuhiro
    Sawa, Daisuke
    Kawano, Yoshifumi
    Okamura, Jun
    PEDIATRIC TRANSPLANTATION, 2012, 16 (07) : 722 - 728
12345